Stem Cells & Differentiation

Stem cells are undifferentiated cells with two defining characteristics: the capacity for self-renewal (can divide to produce identical daughter stem cells) and potency (can give rise to one or more specialised cell types). Understanding stem cell biology has transformed our knowledge of development, tissue homeostasis, and disease, and has opened the possibility of regenerative medicine.

Classification by Potency

Totipotent stem cells can give rise to all cell types of the embryo and placenta, including extraembryonic tissues. In humans, totipotency is restricted to the fertilised egg (zygote) and the blastomeres of the 2–4 cell embryo.

Pluripotent stem cells can give rise to all three germ layers (ectoderm, mesoderm, endoderm) and thus virtually all cell types of the body, but cannot form extraembryonic tissues. Embryonic stem cells (ESCs) are derived from the inner cell mass (ICM) of the blastocyst (days 5–7 of human development). ESCs maintain pluripotency through a transcriptional network centred on the transcription factors OCT4 (POU5F1), SOX2, and NANOG. ESCs can be propagated indefinitely in culture and differentiated into any cell type — enormous research potential but ethically controversial due to embryo destruction, and immunological rejection remains a barrier to therapeutic use.

Multipotent stem cells can generate multiple cell types but only those of a particular lineage. Haematopoietic stem cells (HSCs): located in the bone marrow, give rise to all blood cell lineages (myeloid and lymphoid). HSC self-renewal is supported by the bone marrow niche (CXCL12/CXCR4 axis, SCF/c-KIT, TPO/MPL signalling). HSCs express CD34+, CD38−, Lin−, CD117+, and SCA1+ (in mice). HSC transplantation is used to treat haematological malignancies (AML, ALL, CML, lymphoma), aplastic anaemia, and immunodeficiency disorders. Mesenchymal stem cells (MSCs) are stromal cells derived from bone marrow, adipose, and other tissues; can differentiate into osteoblasts, chondrocytes, and adipocytes. Neural stem cells (NSCs) are present in restricted niches in the adult brain (subventricular zone, dentate gyrus of hippocampus) and can generate neurons and glia.

Unipotent stem cells give rise to a single cell type — e.g., spermatogonial stem cells (spermatocytes only), hepatocyte progenitor cells.

Induced Pluripotent Stem Cells (iPSCs)

A landmark discovery by Shinya Yamanaka (2006, Nobel Prize 2012): adult somatic cells (e.g., skin fibroblasts) can be reprogrammed to a pluripotent state by forced expression of four transcription factors — OCT4, SOX2, KLF4, and c-MYC (the "Yamanaka factors"). The resulting iPSCs are essentially equivalent to ESCs in terms of gene expression, epigenome, and developmental potential. iPSC technology avoids the ethical issues of embryo use and, crucially, can generate patient-specific (autologous) stem cells, potentially eliminating the need for immunosuppression in cell therapy.

Applications: Disease modelling (patient-derived iPSCs carrying disease mutations can be differentiated into the affected cell type in vitro — "disease in a dish" — for mechanistic studies and drug screening); drug toxicity testing; and, in the future, cell therapy (iPSC → cardiomyocytes for heart failure; iPSC → β cells for T1DM; iPSC → dopaminergic neurons for Parkinson's).

Challenges: iPSC generation efficiency is low (~0.01–0.1%); reprogramming can introduce mutations; epigenetic memory of the parental cell type; risk of tumorigenesis from persistent pluripotent cells or c-MYC reactivation; manufacturing scalability and cost.

Differentiation Pathways

Cell fate decisions are controlled by transcription factor networks, signalling pathways, and epigenetic reprogramming. During embryonic development, the three germ layers — ectoderm (surface ectoderm → epidermis, hair, teeth; neuroectoderm → CNS, PNS, neural crest → craniofacial, cardiac ganglia, melanocytes, peripheral neurons), mesoderm (heart, skeletal muscle, bone, cartilage, kidney, gonads, spleen, haematopoietic system), and endoderm (respiratory epithelium, GI epithelium, liver, pancreas, thyroid) — arise from the pluripotent epiblast through gastrulation.

Key signals: Wnt (mesodermal induction, intestinal stem cell maintenance); BMP (epidermal fate, inhibits neural induction); Notch (lateral inhibition, determines cell fate between adjacent cells — e.g., tip cells vs stalk cells in angiogenesis; neuronal vs glial fate); Hedgehog (Shh) (floor plate induction, neural patterning, dorsal-ventral patterning of limbs); FGF (mesodermal induction, limb growth); RA (retinoic acid) (anterior-posterior patterning of the neural tube and hindbrain, segmentation).

Haematopoietic differentiation proceeds hierarchically from HSC → multipotent progenitors (MPP) → common myeloid progenitor (CMP, gives rise to erythrocytes, megakaryocytes, granulocytes, monocytes) and common lymphoid progenitor (CLP, gives rise to B cells, T cells, NK cells). Each transition is driven by lineage-specific transcription factors: GATA1 (erythroid/megakaryocyte), C/EBPα (granulocyte), PU.1 (monocyte/macrophage), PAX5 (B cell commitment), NOTCH1 (T cell commitment, thymus).

Stem Cells in Cancer: Cancer Stem Cells

The cancer stem cell (CSC) hypothesis proposes that tumours are organised hierarchically, with a small subpopulation of CSCs at the apex that drive tumour initiation, maintenance, and relapse. CSCs share properties with normal stem cells: self-renewal, expression of stem cell markers (CD44⁺/CD24⁻ in breast cancer, CD133⁺ in glioblastoma, CD34⁺/CD38⁻ in AML), and resistance to conventional chemotherapy and radiotherapy (due to enhanced DNA repair, upregulated ABC drug transporters, quiescence). After treatment, residual CSCs can regenerate the tumour, explaining relapse. Therapeutic strategies targeting CSCs include Notch and Hedgehog pathway inhibitors, and anti-CD44/CD33 antibodies (e.g., gemtuzumab ozogamicin targets CD33 in AML).

Clinical Applications of Stem Cells

Haematopoietic stem cell transplantation (HSCT): Autologous (patient's own HSCs collected, stored, then re-infused after high-dose chemotherapy — myeloma, lymphoma) or allogeneic (donor HSCs — AML, ALL, aplastic anaemia — graft-versus-leukaemia effect is therapeutic, but graft-versus-host disease is a major complication). CAR-T cell therapy: T cells genetically engineered with chimeric antigen receptors (CARs) targeting tumour-specific antigens (CD19 for B-ALL and DLBCL; BCMA for myeloma) — manufactured from patient's own T cells, not strictly stem cells but represent a form of cell-based immunotherapy. Gene therapy combined with stem cells: For monogenic diseases, autologous HSCs are edited ex vivo (lentiviral gene addition — ADA-SCID, β-thalassaemia; or CRISPR-based correction) then re-infused. Betibeglogene autotemcel (betibeglogene, Zynteglo) uses lentiviral β-globin gene addition into HSCs for transfusion-dependent β-thalassaemia. Exagamglogene autotemcel (Casgevy) uses CRISPR to reactivate fetal haemoglobin in HSCs for sickle-cell disease and β-thalassaemia.